Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ferric Derisomaltose
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
April 16, 2025
Lead Product(s) : Ferric Derisomaltose
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Trilaciclib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : G1 Therapeutics, Inc
Deal Size : $405.0 million
Deal Type : Acquisition
Pharmacosmos Group to Acquire G1 Therapeutics
Details : Through the acquisition, Pharmacosmos will leverage G1' intellectual property and the addition of Cosela (trilaciclib), which is indicated for treating metastatic triple-negative breast cancer.
Product Name : Cosela
Product Type : Other Small Molecule
Upfront Cash : $405.0 million
July 08, 2024
Lead Product(s) : Trilaciclib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : G1 Therapeutics, Inc
Deal Size : $405.0 million
Deal Type : Acquisition
Lead Product(s) : Ferric Derisomaltose
Therapeutic Area : Hematology
Study Phase : Phase IV
Recipient : Peking Union Medical College Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
The Effects of Ferric Derisomaltose on Postoperative Anemia in Spinal Deformity Surgery
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
February 06, 2023
Lead Product(s) : Ferric Derisomaltose
Therapeutic Area : Hematology
Highest Development Status : Phase IV
Recipient : Peking Union Medical College Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SP-420
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Icon Plc
Deal Size : Inapplicable
Deal Type : Inapplicable
A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 23, 2023
Lead Product(s) : SP-420
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Icon Plc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ferric Derisomaltose
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Zydus Lifesciences
Deal Size : Undisclosed
Deal Type : Acquisition
Zydus Buys Rights from Pharmacosmos to Sell Drug to Treat Anemia in India, Nepal
Details : MonoFerric injection having Ferric derisomaltose, is a rapid, single dose intravenous therapy used for the treatment of iron deficiency in adult patients when oral iron preparations are ineffective or cannot be used.
Product Name : MonoFerric
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Undisclosed
September 09, 2022
Lead Product(s) : Ferric Derisomaltose
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Zydus Lifesciences
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Ferric Derisomaltose
Therapeutic Area : Oncology
Study Phase : Phase III
Recipient : Alberta Health services
Deal Size : Inapplicable
Deal Type : Inapplicable
Ferric Derisomaltose/Iron Isomaltoside and Outcomes in the Recovery of Gynecologic Oncology ERAS
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
July 20, 2022
Lead Product(s) : Ferric Derisomaltose
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Alberta Health services
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ferric Derisomaltose
Therapeutic Area : Hematology
Study Phase : Phase IV
Recipient : Brigham and Women's Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Preoperative Monoferric for Abdominal Surgery
Details : Undisclosed
Product Name : Monoferric
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
February 28, 2022
Lead Product(s) : Ferric Derisomaltose
Therapeutic Area : Hematology
Highest Development Status : Phase IV
Recipient : Brigham and Women's Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ferric Derisomaltose
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
January 05, 2022
Lead Product(s) : Ferric Derisomaltose
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ferric Derisomaltose
Therapeutic Area : Hematology
Study Phase : Phase IV
Recipient : P. Noordzij
Deal Size : Inapplicable
Deal Type : Inapplicable
Intravenous Iron to Treat Postoperative Anemia in Older Cardiac Surgery Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
June 04, 2021
Lead Product(s) : Ferric Derisomaltose
Therapeutic Area : Hematology
Highest Development Status : Phase IV
Recipient : P. Noordzij
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ferric Derisomaltose
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Monofer® is the first of the latest generation of innovative IV irons to be made available to patients in the Chinese health care system and is expected to expand the use of IV irons across multiple therapeutic areas.
Product Name : Monofer
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
January 29, 2021
Lead Product(s) : Ferric Derisomaltose
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable